Daniel S. Levine
@dslevine.bsky.social
Principal, Levine Media Group, host of The Bio Report and RARECast podcasts, award-winning journalist focused on the life sciences.
Atta Behfar, co-founder and CEO of Rion, discusses how the company’s purified exosome products work, their potential as scalable and cost-effective regenerative therapies, and how they avoid the immune issues that have long hampered cell-based approaches.
thebioreport.podbean.com/e/separating...
thebioreport.podbean.com/e/separating...
December 3, 2025 at 3:32 PM
Atta Behfar, co-founder and CEO of Rion, discusses how the company’s purified exosome products work, their potential as scalable and cost-effective regenerative therapies, and how they avoid the immune issues that have long hampered cell-based approaches.
thebioreport.podbean.com/e/separating...
thebioreport.podbean.com/e/separating...
Mo Jain, chief scientific officer of Sapient, discusses how its technology bridges the gap from discovery to clinical development, accelerates drug development timelines, and expands opportunities to drug previously undruggable targets.
thebioreport.podbean.com/e/rewriting-...
thebioreport.podbean.com/e/rewriting-...
November 26, 2025 at 3:58 PM
Mo Jain, chief scientific officer of Sapient, discusses how its technology bridges the gap from discovery to clinical development, accelerates drug development timelines, and expands opportunities to drug previously undruggable targets.
thebioreport.podbean.com/e/rewriting-...
thebioreport.podbean.com/e/rewriting-...
Dan Schmitt, CEO of Actuate Therapeutics, discusses the company’s experimental therapy elraglusib’s potential to overcome chemoresistance, its recent clinical successes in metastatic pancreatic cancer, and the drug’s unique multimodal mechanism.
thebioreport.podbean.com/e/overcoming...
thebioreport.podbean.com/e/overcoming...
November 19, 2025 at 4:45 PM
Dan Schmitt, CEO of Actuate Therapeutics, discusses the company’s experimental therapy elraglusib’s potential to overcome chemoresistance, its recent clinical successes in metastatic pancreatic cancer, and the drug’s unique multimodal mechanism.
thebioreport.podbean.com/e/overcoming...
thebioreport.podbean.com/e/overcoming...
Theresa Heah, CEO of Eyexora, discusses the hub-and-spoke business model, the company’s initial assets in-licensed from the Singapore Eye Research Institute, and how it identifies early-stage candidates with high potential.
thebioreport.podbean.com/e/a-hub-and-...
thebioreport.podbean.com/e/a-hub-and-...
November 12, 2025 at 2:56 PM
Theresa Heah, CEO of Eyexora, discusses the hub-and-spoke business model, the company’s initial assets in-licensed from the Singapore Eye Research Institute, and how it identifies early-stage candidates with high potential.
thebioreport.podbean.com/e/a-hub-and-...
thebioreport.podbean.com/e/a-hub-and-...
Brian Weitzner, co-founder of OpenFold, discusses the collaborative effort to develop software and AI tools to predict the 3D structure of proteins, how its open licensing model ensures broad accessibility, and how it stacks up against AlphaFold.
thebioreport.podbean.com/e/an-ai-coll...
thebioreport.podbean.com/e/an-ai-coll...
November 5, 2025 at 3:24 PM
Brian Weitzner, co-founder of OpenFold, discusses the collaborative effort to develop software and AI tools to predict the 3D structure of proteins, how its open licensing model ensures broad accessibility, and how it stacks up against AlphaFold.
thebioreport.podbean.com/e/an-ai-coll...
thebioreport.podbean.com/e/an-ai-coll...
John Hoekman, co-founder and CEO of Junevity, discusses the role of transcription factors in healthy biology and aging-related disease, the company’s AI-driven platform, and its lead programs targeting type 2 diabetes and obesity.
thebioreport.podbean.com/e/hitting-th...
thebioreport.podbean.com/e/hitting-th...
October 29, 2025 at 3:10 PM
John Hoekman, co-founder and CEO of Junevity, discusses the role of transcription factors in healthy biology and aging-related disease, the company’s AI-driven platform, and its lead programs targeting type 2 diabetes and obesity.
thebioreport.podbean.com/e/hitting-th...
thebioreport.podbean.com/e/hitting-th...
Stacy Lindborg, CEO of Imunon, discusses the company’s DNA-mediated immunotherapy, how it avoids the systemic toxicities that undermined earlier IL-12 approaches, and how it could change the treatment landscape for the disease.
thebioreport.podbean.com/e/changing-t...
thebioreport.podbean.com/e/changing-t...
October 22, 2025 at 2:23 PM
Stacy Lindborg, CEO of Imunon, discusses the company’s DNA-mediated immunotherapy, how it avoids the systemic toxicities that undermined earlier IL-12 approaches, and how it could change the treatment landscape for the disease.
thebioreport.podbean.com/e/changing-t...
thebioreport.podbean.com/e/changing-t...
Marc Salzberg, CEO of Airway Therapeutics, discusses the company’s experimental therapy zelpultide alfa to treat preterm infants with a rare lung disease, why it’s a pipeline-in-a-product, and its development path forward.
thebioreport.podbean.com/e/scratching...
thebioreport.podbean.com/e/scratching...
October 1, 2025 at 2:07 PM
Marc Salzberg, CEO of Airway Therapeutics, discusses the company’s experimental therapy zelpultide alfa to treat preterm infants with a rare lung disease, why it’s a pipeline-in-a-product, and its development path forward.
thebioreport.podbean.com/e/scratching...
thebioreport.podbean.com/e/scratching...
Rohan Palekar, CEO of 89bio, discusses what’s driving the prevalence of MASH, the limits of existing medicines, and how the company’s experimental therapy targets both liver fibrosis and the underlying metabolic dysfunctions of the disease.
thebioreport.podbean.com/e/a-dual-act...
thebioreport.podbean.com/e/a-dual-act...
September 24, 2025 at 2:16 PM
Rohan Palekar, CEO of 89bio, discusses what’s driving the prevalence of MASH, the limits of existing medicines, and how the company’s experimental therapy targets both liver fibrosis and the underlying metabolic dysfunctions of the disease.
thebioreport.podbean.com/e/a-dual-act...
thebioreport.podbean.com/e/a-dual-act...
Steve Perrin, CSO of Eledon Pharmaceuticals, discusses the need for innovative approaches to immunosuppression in organ transplantation, how its experimental therapy works, and why it may have benefits in autoimmune and neurodegenerative diseases as well.
thebioreport.podbean.com/e/extending-...
thebioreport.podbean.com/e/extending-...
September 17, 2025 at 4:15 PM
Steve Perrin, CSO of Eledon Pharmaceuticals, discusses the need for innovative approaches to immunosuppression in organ transplantation, how its experimental therapy works, and why it may have benefits in autoimmune and neurodegenerative diseases as well.
thebioreport.podbean.com/e/extending-...
thebioreport.podbean.com/e/extending-...
David Jenkinson of @lifearc.bsky.social discusses the children’s cancer therapeutics consortium C-Further, the challenges of developing treatments for childhood cancers, and why new models for advancing these therapies are needed. @globalgenes.bsky.social #RARECast
open.spotify.com/episode/13td...
open.spotify.com/episode/13td...
September 12, 2025 at 3:06 PM
David Jenkinson of @lifearc.bsky.social discusses the children’s cancer therapeutics consortium C-Further, the challenges of developing treatments for childhood cancers, and why new models for advancing these therapies are needed. @globalgenes.bsky.social #RARECast
open.spotify.com/episode/13td...
open.spotify.com/episode/13td...
Greg Mario, CEO of Taxis Pharmaceuticals, discusses the public health threat posed by drug-resistant gonorrhea, the approaches it’s taking to develop new antimicrobial treatments, and the need for new funding models to bring new therapies to market.
thebioreport.podbean.com/e/overcoming...
thebioreport.podbean.com/e/overcoming...
September 10, 2025 at 2:25 PM
Greg Mario, CEO of Taxis Pharmaceuticals, discusses the public health threat posed by drug-resistant gonorrhea, the approaches it’s taking to develop new antimicrobial treatments, and the need for new funding models to bring new therapies to market.
thebioreport.podbean.com/e/overcoming...
thebioreport.podbean.com/e/overcoming...
Marc Hedrick, president and CEO of Plus Therapeutics, Inc., discusses the challenges of treating brain tumors, the limitations of current therapies, and why the company’s targeted radiotherapies have the potential to create better outcomes for patients.
thebioreport.podbean.com/e/using-targ...
thebioreport.podbean.com/e/using-targ...
September 3, 2025 at 6:22 PM
Marc Hedrick, president and CEO of Plus Therapeutics, Inc., discusses the challenges of treating brain tumors, the limitations of current therapies, and why the company’s targeted radiotherapies have the potential to create better outcomes for patients.
thebioreport.podbean.com/e/using-targ...
thebioreport.podbean.com/e/using-targ...
Morten Graugaard, co-founder and CEO of Orbis Medicines, discusses its class of synthetic macrocycles, called nCycles, its platform technology for generating and screening these therapies, and how they can offer an orally delivered alternative to biologics.
thebioreport.podbean.com/e/hitting-pr...
thebioreport.podbean.com/e/hitting-pr...
August 27, 2025 at 2:21 PM
Morten Graugaard, co-founder and CEO of Orbis Medicines, discusses its class of synthetic macrocycles, called nCycles, its platform technology for generating and screening these therapies, and how they can offer an orally delivered alternative to biologics.
thebioreport.podbean.com/e/hitting-pr...
thebioreport.podbean.com/e/hitting-pr...
Stacey Adam of the Foundation for the National Institutes of Health, discusses the public-private partnership she is leading to advance alternatives to animal testing, the technologies they are exploring, and their potential to accelerate drug development.
thebioreport.podbean.com/e/building-b...
thebioreport.podbean.com/e/building-b...
August 20, 2025 at 2:34 PM
Stacey Adam of the Foundation for the National Institutes of Health, discusses the public-private partnership she is leading to advance alternatives to animal testing, the technologies they are exploring, and their potential to accelerate drug development.
thebioreport.podbean.com/e/building-b...
thebioreport.podbean.com/e/building-b...
Lorin Johnson of Glycyx discusses the effect of opioids on the immune system and the company’s experimental therapy designed to mitigate the negative effects of opioids in cancer patients being treated with checkpoint inhibitors.
thebioreport.podbean.com/e/preventing...
thebioreport.podbean.com/e/preventing...
August 13, 2025 at 2:47 PM
Lorin Johnson of Glycyx discusses the effect of opioids on the immune system and the company’s experimental therapy designed to mitigate the negative effects of opioids in cancer patients being treated with checkpoint inhibitors.
thebioreport.podbean.com/e/preventing...
thebioreport.podbean.com/e/preventing...
Abbas Kazimi, CEO Nimbus Therapeutics, discusses how the company’s drug discovery approach has evolved with AI, its deal making successes, and how its business model provides liquidity to investors and while making it easier to structure deals.
thebioreport.podbean.com/e/better-liv...
thebioreport.podbean.com/e/better-liv...
August 6, 2025 at 3:32 PM
Abbas Kazimi, CEO Nimbus Therapeutics, discusses how the company’s drug discovery approach has evolved with AI, its deal making successes, and how its business model provides liquidity to investors and while making it easier to structure deals.
thebioreport.podbean.com/e/better-liv...
thebioreport.podbean.com/e/better-liv...
Juho Jalkanen, founder and CEO of Faron, discusses how the tumor microenvironment can suppress macrophages, how the company’s macrophage checkpoint inhibitor works, and the challenges a Finland-based company faces accessing the capital markets.
thebioreport.podbean.com/e/outsmartin...
thebioreport.podbean.com/e/outsmartin...
July 30, 2025 at 2:25 PM
Juho Jalkanen, founder and CEO of Faron, discusses how the tumor microenvironment can suppress macrophages, how the company’s macrophage checkpoint inhibitor works, and the challenges a Finland-based company faces accessing the capital markets.
thebioreport.podbean.com/e/outsmartin...
thebioreport.podbean.com/e/outsmartin...
Jenny Marlowe and Melissa Bonner of nChroma Bio discuss the company’s experimental epigenetic editor for hepatitis B, the merger that formed the company, and how it married an epigenetic editing platform with programmable non-viral delivery technologies.
thebioreport.podbean.com/e/crafting-a...
thebioreport.podbean.com/e/crafting-a...
July 16, 2025 at 4:12 PM
Jenny Marlowe and Melissa Bonner of nChroma Bio discuss the company’s experimental epigenetic editor for hepatitis B, the merger that formed the company, and how it married an epigenetic editing platform with programmable non-viral delivery technologies.
thebioreport.podbean.com/e/crafting-a...
thebioreport.podbean.com/e/crafting-a...
Niven Narain, CEO of BPGbio, discusses how the company’s platform technology uncovers novel targets, its evolution from its start as Berg, and how the platform continues to provide insight into experimental therapies after they advance to the clinic.
thebioreport.podbean.com/e/fueling-ai...
thebioreport.podbean.com/e/fueling-ai...
July 9, 2025 at 3:28 PM
Niven Narain, CEO of BPGbio, discusses how the company’s platform technology uncovers novel targets, its evolution from its start as Berg, and how the platform continues to provide insight into experimental therapies after they advance to the clinic.
thebioreport.podbean.com/e/fueling-ai...
thebioreport.podbean.com/e/fueling-ai...
Steve Ruston, CEO of Persica Pharmaceuticals, discusses the need for new approaches to chronic low back pain, the company’s experimental targeted antibiotic injections, and the need to educate physicians about the role infection can play in the condition.
thebioreport.podbean.com/e/a-novel-ap...
thebioreport.podbean.com/e/a-novel-ap...
June 25, 2025 at 1:18 PM
Steve Ruston, CEO of Persica Pharmaceuticals, discusses the need for new approaches to chronic low back pain, the company’s experimental targeted antibiotic injections, and the need to educate physicians about the role infection can play in the condition.
thebioreport.podbean.com/e/a-novel-ap...
thebioreport.podbean.com/e/a-novel-ap...
Barry Quart, CEO of Connect Biopharma, discusses the unmet need in asthma and COPD, the company’s experimental therapy rademikibart, and the case for a biologic that can address acute exacerbations of these conditions.
thebioreport.podbean.com/e/a-biologic...
thebioreport.podbean.com/e/a-biologic...
June 18, 2025 at 1:24 PM
Barry Quart, CEO of Connect Biopharma, discusses the unmet need in asthma and COPD, the company’s experimental therapy rademikibart, and the case for a biologic that can address acute exacerbations of these conditions.
thebioreport.podbean.com/e/a-biologic...
thebioreport.podbean.com/e/a-biologic...
Matthew Shaulis, general manager of North America for BeOne Medicines, discusses the significant global disparities in cancer care, and the opportunities and challenges of taking a global approach to marketing innovative medicines.
thebioreport.podbean.com/e/making-med...
thebioreport.podbean.com/e/making-med...
May 28, 2025 at 2:33 PM
Matthew Shaulis, general manager of North America for BeOne Medicines, discusses the significant global disparities in cancer care, and the opportunities and challenges of taking a global approach to marketing innovative medicines.
thebioreport.podbean.com/e/making-med...
thebioreport.podbean.com/e/making-med...
Daniel Getts, founder and CEO of Myeloid Therapeutics, discusses the limitations of existing immunotherapies, the role myeloid cells play in the immune system, and the benefits of harnessing them to fight cancers.
thebioreport.podbean.com/e/harnessing...
thebioreport.podbean.com/e/harnessing...
May 21, 2025 at 4:20 PM
Daniel Getts, founder and CEO of Myeloid Therapeutics, discusses the limitations of existing immunotherapies, the role myeloid cells play in the immune system, and the benefits of harnessing them to fight cancers.
thebioreport.podbean.com/e/harnessing...
thebioreport.podbean.com/e/harnessing...
Tech entrepreneur-turned-historian Ronald Gruner discusses his new book “COVID Wars: America’s Struggle Over Public Health and Personal Freedom,” what the public data surrounding the pandemic tells us, and the lessons to be learned.
thebioreport.podbean.com/e/drawing-le...
thebioreport.podbean.com/e/drawing-le...
May 14, 2025 at 3:45 PM
Tech entrepreneur-turned-historian Ronald Gruner discusses his new book “COVID Wars: America’s Struggle Over Public Health and Personal Freedom,” what the public data surrounding the pandemic tells us, and the lessons to be learned.
thebioreport.podbean.com/e/drawing-le...
thebioreport.podbean.com/e/drawing-le...